stoxline Quote Chart Rank Option Currency Glossary
  
HOOKIPA Pharma Inc. (HOOK)
1.27  -0.035 (-2.68%)    06-20 12:50
Open: 1.305
High: 1.31
Volume: 52,027
  
Pre. Close: 1.305
Low: 1.25
Market Cap: 15(M)
Technical analysis
2025-06-20 12:17:28 PM
Short term     
Mid term     
Targets 6-month :  1.83 1-year :  2.06
Resists First :  1.57 Second :  1.76
Pivot price 1.47
Supports First :  1.25 Second :  1.03
MAs MA(5) :  1.35 MA(20) :  1.5
MA(100) :  1.36 MA(250) :  2.96
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  1.4 D(3) :  10.2
RSI RSI(14): 38.4
52-week High :  6.8 Low :  0.72
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HOOK ] has closed below the lower bollinger band by 2.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ HOOK ] is to continue within current trading range. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.31 - 1.31 1.31 - 1.32
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.29 - 1.31 1.31 - 1.32
Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Headline News

Fri, 23 May 2025
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey

Thu, 22 May 2025
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha

Mon, 07 Apr 2025
Hookipa Pharma stock hits 52-week low at $0.81 amid sharp decline - Investing.com

Wed, 05 Mar 2025
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline - Investing.com

Fri, 28 Feb 2025
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView

Thu, 27 Feb 2025
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 10 (M)
Shares Float 10 (M)
Held by Insiders 19.2 (%)
Held by Institutions 34.2 (%)
Shares Short 189 (K)
Shares Short P.Month 13 (K)
Stock Financials
EPS -5.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.71
Profit Margin 0 %
Operating Margin -885.3 %
Return on Assets (ttm) -45.3 %
Return on Equity (ttm) -105.8 %
Qtrly Rev. Growth -94.5 %
Gross Profit (p.s.) -5.16
Sales Per Share 0.95
EBITDA (p.s.) -7.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -53 (M)
Levered Free Cash Flow -33 (M)
Stock Valuations
PE Ratio -0.22
PEG Ratio 0
Price to Book value 0.46
Price to Sales 1.3
Price to Cash Flow -0.24
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android